Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. BEAT
BEAT logo

BEAT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Heartbeam Inc (BEAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.360
1 Day change
0.74%
52 Week Range
4.000
Analysis Updated At
2026/03/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Heartbeam Inc (BEAT) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, weak technical indicators, absence of significant trading trends, and no recent news or catalysts make this stock less appealing for long-term investment. Additionally, the stock's recent price trend and lack of proprietary trading signals do not provide a compelling entry point.

Technical Analysis

The MACD histogram is positive but contracting, RSI is neutral at 39.74, and moving averages are converging, indicating no clear trend. The stock is trading below its pivot level of 1.524, with key support at 1.351 and resistance at 1.697.

Positive Catalysts

  • NULL identified. No recent news, events, or trading trends to act as positive catalysts.

Neutral/Negative Catalysts

  • The stock experienced an 8.50% drop in the regular market session, with no significant news or events to explain the decline. Financial performance remains weak, with no revenue growth and declining EPS.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income improved slightly YoY but remains negative at -$5.26M. EPS dropped by 21.05% YoY to -0.15, and gross margin remains at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available on analyst ratings or price target changes.

Wall Street analysts forecast BEAT stock price to rise
3 Analyst Rating
Wall Street analysts forecast BEAT stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.350
sliders
Low
4
Averages
5.83
High
8
Current: 1.350
sliders
Low
4
Averages
5.83
High
8
Roth Capital
NULL -> Buy
initiated
$4
AI Analysis
2025-10-31
Reason
Roth Capital
Price Target
$4
AI Analysis
2025-10-31
initiated
NULL -> Buy
Reason
Roth Capital initiated coverage of HeartBeam with a Buy rating and $4 price target. The company is developing a credit-card-sized, cable-free cardiac device that synthesizes a 12-lead electrocardiogram, the analyst tells investors in a research note. The firm expects FDA clearance in the "coming days" that will initially focus on advanced cardiac arrhythmias within the concierge medicine market.

People Also Watch